In vitro studies evaluating the interaction between ZD1839 ('Iressa') and ionizing radiation

被引：0
|
作者：
Giocanti, N
Hennequin, C
Defrance, R
Favaudon, V
机构：
[1] Inst Curie Rech, U 350 INSERM, Orsay, France
[2] Hop St Louis, Serv Cancerol Radiotherapie, Paris, France
[3] AstraZeneca, Rueil Malmaison, France
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
186
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] ZD1839 (IRESSA™):: Preclinical studies and pharmacology
    Ciardiello, F
    Tortora, G
    De Placido, S
    Bianco, AR
    TUMORI, 2002, 88 (01) : S155 - S157
  • [2] Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
    N Giocanti
    C Hennequin
    D Rouillard
    R Defrance
    V Favaudon
    British Journal of Cancer, 2004, 91 : 2026 - 2033
  • [3] Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro
    Giocanti, N
    Hennequin, C
    Rouillard, D
    Defrance, R
    Favaudon, V
    BRITISH JOURNAL OF CANCER, 2004, 91 (12) : 2026 - 2033
  • [4] Targeting molecular therapy by Iressa® (ZD1839)
    Fayette, J
    Soria, JC
    M S-MEDECINE SCIENCES, 2003, 19 (11): : 1052 - 1054
  • [5] Gefitinib ('Iressa', ZD1839): the patients' experience
    Goss, G
    EJC SUPPLEMENTS, 2003, 1 (08): : 29 - 33
  • [6] ZD1839 (Iressa™):: What's in it for the patient?
    Natale, RB
    Zaretsky, SL
    ONCOLOGIST, 2002, 7 : 25 - 30
  • [7] Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil
    Magné, N
    Fischel, JL
    Tiffon, C
    Formento, P
    Dubreuil, A
    Renée, N
    Formento, JL
    Francoual, M
    Ciccolini, J
    Etienne, MC
    Milano, G
    BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 585 - 592
  • [8] Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
    N Magné
    J-L Fischel
    C Tiffon
    P Formento
    A Dubreuil
    N Renée
    J-L Formento
    M Francoual
    J Ciccolini
    M-C Etienne
    G Milano
    British Journal of Cancer, 2003, 89 : 585 - 592
  • [9] Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin
    Xu, JM
    Azzariti, A
    Severino, M
    Lu, B
    Colucci, G
    Paradiso, A
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (04) : 551 - 563
  • [10] Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells
    Park, JK
    Lee, SH
    Kang, JH
    Nishio, K
    Saijo, N
    Kuh, HJ
    ANTI-CANCER DRUGS, 2004, 15 (08) : 809 - 818
12345